Related Experiment Video
Updated: Jan 8, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Association between the Use of Fondaparinux Plus Radial Access and Clinical Outcomes in Patients with Non-ST
Luiz Eduardo Fonteles Ritt1,2, Eduardo Sahade Darze1,2, Pedro Gabriel Melo de Barros E Silva3
1Instituto D'Or de Pesquisa e Ensino, Hospital Cardio Pulmonar, BA - Brasil.
Insights
Combining fondaparinux and radial access significantly lowers major adverse cardiovascular events (MACE) and bleeding in acute coronary syndrome (ACS) patients. This strategy offers superior outcomes compared to other anticoagulation and access site combinations.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Fondaparinux and radial access are individually linked to reduced major adverse cardiovascular events (MACE) in acute coronary syndrome (ACS).
- Investigating the combined effect of these strategies is crucial for optimizing patient care in ACS.
Purpose of the Study:
- To evaluate the combined impact of fondaparinux and radial access on clinical outcomes in ACS patients.
- To compare the efficacy and safety of fondaparinux plus radial access against other anticoagulation and arterial access combinations.
Main Methods:
- Analysis of 956 ACS patients undergoing invasive procedures.
- Primary outcome: composite of major bleeding (OASIS-5 criteria) and MACE.
- Comparison across four groups: fondaparinux/enoxaparin with femoral/radial access.
Main Results:
- The combination of fondaparinux and radial access demonstrated the lowest event rate (3.3%).
- Fondaparinux use was associated with a 43% reduction in the primary outcome (OR, 0.57; p < 0.05).
- Radial access independently reduced the primary outcome by 54% (OR, 0.46; p = 0.01).
Conclusions:
- The concurrent use of fondaparinux and radial access is associated with the lowest rates of MACE and major bleeding in ACS.
- This combination strategy appears superior to using either fondaparinux or radial access alone, or in combination with enoxaparin or femoral access, respectively.
Background:
Both fondaparinux and radial access have been associated with lower rates of major adverse cardiovascular events (MACE) in acute coronary syndrome (ACS).
Objective:
To evaluate the association between the use of fondaparinux plus radial access and clinical outcomes.
Methods:
In this study, 956 patients admitted with ACS and treated with an invasive strategy were analyzed. The primary outcome - a composite of major bleeding (according to OASIS-5 criteria) and MACE - was compared across groups defined by anticoagulation regimen (fondaparinux or enoxaparin) plus arterial access site (femoral vs. radial). A p-value < 0.05 was considered statistically significant.
Results:
The mean age of the study population was 65 ± 12.4 years, and 49.5% presented with non-ST segment elevation myocardial infarction (NSTEMI). Fondaparinux and radial access were used concurrently in 366 patients. The primary endpoint occurred in 78 patients (8.1%): MACE in 50 (5.2%) and major bleeding in 32 (3.3%). The event rate was lowest in the fondaparinux plus radial access group (3.3%), compared with enoxaparin plus radial access (9.8%), fondaparinux plus femoral access (8.6%), and enoxaparin plus femoral access (14.4%) (p < 0.001). Multivariable analysis showed that the use of fondaparinux was associated with a 43% reduction in the primary outcome (OR, 0.57; 95% CI, 0.34-0.96; p < 0.05), and radial access was independently associated with a 54% reduction (OR, 0.46; 95% CI, 0.26-0.83; p = 0.01).
Conclusion:
The combination of fondaparinux and radial access was associated with the lowest rates of MACE and major bleeding, compared to either strategy alone.
More Related Videos
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management

